Investigation for Investors in shares of Celladon Corp (NASDAQ:CLDN) over Acquisition announced
The takeover of Celladon is under investigation over potential wrongdoing. The investigation was announced on behalf of investors, who currently hold NASDAQ:CLDN shares concerning whether the takeover of Celladon Corp. is unfair to NASDAQ:CLDN stockholders.
Investors who purchased shares of Celladon Corp (NASDAQ:CLDN) and currently hold any of those NASDAQ:CLDN shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain officers and directors of Celladon Corp breached their fiduciary duties owed to NASDAQ:CLDN investors in connection with the proposed acquisition.
On November 18, 2015 Celladon Corp (NASDAQ:CLDN) and Eiger BioPharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a merger agreement under which the stockholders of Eiger would become the majority owners of Celladon, and the operations of Celladon and Eiger would be combined.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.